The continuing importance of bile acids in liver and intestinal disease

被引:746
作者
Hofmann, AF [1 ]
机构
[1] Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA
关键词
D O I
10.1001/archinte.159.22.2647
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bile acids, the water-soluble, amphipathic end products of cholesterol metabolism, are involved in liver, biliary, and intestinal disease. Formed in the liver, bile acids are absorbed actively from the small intestine, with each molecule undergoing multiple enterohepatic circulations before being excreted. After their synthesis from cholesterol, bile acids are conjugated with glycine or taurine, a process that makes them impermeable to cell membranes and permits high concentrations to persist in bile and intestinal content. The relation between the chemical structure and the multiple physiological functions of bile acids is reviewed. Bile acids induce biliary lipid secretion and solubilize cholesterol in bile, promoting its elimination. In the small intestine, bile acids solubilize dietary lipids promoting their absorption. Bile acids are cytotoxic when present in abnormally high concentrations. This may occur intracellularly, as occurs in the hepatocyte in cholestasis, or extracellulary, as occurs in the colon in patients with bile acid malabsorption. Disturbances in bile acid metabolism can be caused by (1) defective biosynthesis from cholesterol or defective conjugation, (2) defective membrane transport in the hepatocyte or ileal enterocyte, (3) defective transport between organs or biliary diversion, and (4) increased bacterial degradation during enterohepatic cycling. Bile acid therapy involves bile acid replacement in deficiency stales or bile acid displacement by ursodeoxycholic acid, a noncytotoxic bile acid. In cholestatic liver disease, administration of ursodeoxycholic acid decreases hepatocyte injury by retained bile acids, improving liver tests, and slowing disease progression. Bile acid malabsorption may lead to high concentrations of bile acids in the colon and impaired colonic mucosal function; bile acid sequestrants provide symptomatic benefit for diarrhea. A knowledge of bile acid physiology and the perturbations of bile acid metabolism in liver and digestive disease should be useful for the internist.
引用
收藏
页码:2647 / 2658
页数:12
相关论文
共 48 条
[1]   A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection [J].
Barnes, D ;
Talenti, D ;
Cammell, G ;
Goormastic, M ;
Farquhar, L ;
Henderson, M ;
Vogt, D ;
Mayes, J ;
Westveer, MK ;
Carey, W .
HEPATOLOGY, 1997, 26 (04) :853-857
[2]   7 alpha-dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones [J].
Berr, F ;
KullakUblick, GA ;
Paumgartner, G ;
Munzing, W ;
Hylemon, PB .
GASTROENTEROLOGY, 1996, 111 (06) :1611-1620
[3]   Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications [J].
Beuers, U ;
Boyer, JL ;
Paumgartner, G .
HEPATOLOGY, 1998, 28 (06) :1449-1453
[4]   LACK OF 3-BETA-HYDROXY-DELTA-5-C-27-STEROID DEHYDROGENASE ISOMERASE IN FIBROBLASTS FROM A CHILD WITH URINARY-EXCRETION OF 3-BETA-HYDROXY-DELTA-5-C-27-BILE ACIDS - A NEW INBORN ERROR OF METABOLISM [J].
BUCHMANN, MS ;
KVITTINGEN, EA ;
NAZER, H ;
GUNASEKARAN, T ;
CLAYTON, PT ;
SJOVALL, J ;
BJORKHEM, I .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (06) :2034-2037
[5]  
Carey Martin C., 1994, P719
[6]   COMPUTER-SIMULATION OF PORTAL VENOUS SHUNTING AND OTHER ISOLATED HEPATOBILIARY DEFECTS OF THE ENTEROHEPATIC CIRCULATION OF BILE-ACIDS USING A PHYSIOLOGICAL PHARMACOKINETIC MODEL [J].
CRAVETTO, C ;
MOLINO, G ;
HOFMANN, AF ;
BELFORTE, G ;
BONA, B .
HEPATOLOGY, 1988, 8 (04) :866-878
[7]   Role of intestinal transit in the pathogenesis of gallbladder stones [J].
Dowling, RH ;
Veysey, MJ ;
Pereira, SP ;
Hussaini, SH ;
Thomas, LA ;
Wass, JAH ;
Murphy, GM .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1997, 11 (01) :57-64
[8]   COMPARISON OF THE PROPORTION OF UNCONJUGATED TO TOTAL SERUM CHOLIC-ACID AND THE [C-14] XYLOSE BREATH TEST IN PATIENTS WITH SUSPECTED SMALL INTESTINAL BACTERIAL OVERGROWTH [J].
EINARSSON, K ;
BERGSTROM, M ;
EKLOF, R ;
NORD, CE ;
BJORKHEM, I .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1992, 52 (05) :425-430
[9]   The role of mdr2 P-glycoprotein in hepatobiliary lipid transport [J].
Elferink, RPJO ;
Tytgat, GNJ ;
Groen, AK .
FASEB JOURNAL, 1997, 11 (01) :19-28
[10]  
FROMM H, 1973, GASTROENTEROLOGY, V64, P1077